ABBV - Gilead Sciences' Acquisition Of Forty Seven Was A Wise Move CD47 Space Is Key Future Cancer Target
Gilead Sciences (GILD) acquired Forty Seven Inc. (FTSV) and paid a total of $4.8 billion to do so. Gilead has continued to do well when it comes to its HIV franchise, but faced significant challenges in other areas like its NASH pipeline. I believe that buying Forty Seven was a smart move that will definitely drive growth for the company. That's because the CD47 "don't eat me" space is starting to heat up with several biotechs exploring the very same space. The best part of all is that Forty Seven